Clinical Study of Alitol for Acute Ischemic Stroke (ASSIST) Launched

On February 23, 2025, the "Alitol Efficacy and Safety Study in Acute Ischemic Stroke Patients (ASSIST)" was officially launched at Beijing Tiantan Hospital of Capital Medical University (BTMU), and a multi-center study will be conducted at the same time. Prof. Wang Yilong, Executive Vice President of Tiantan Hospital, is the principal investigator of the study, which is a clinical study of Darwin's biologic neuroprosthetic biopharmaceutical "Alitol" in the treatment of stroke and improvement of healing and recovery after the mechanism study based on the efficacy of ALS.

Professor Ren Lijie's team from Shenzhen Second People's Hospital, Professor Song Bo's team from Henan Hospital of Beijing Tiantan Hospital, Professor Xu Jie's team from Anhui Hospital of Beijing Tiantan Hospital, Wang Yu, Chairman of the Company, co-founder and head of the Clinical Department, Li Jianjun, head of the Industrial Center, Li Fuluan, and Chen Yanbo, Director of the Laboratory, together with their teams; and industry experts such as Lv Zhi, Partner of Tsinghua Ginkgo Venture Capital Fund, Chen Maoguo, Director of Investment, Shijingshan Luo Xinjie, Investment Director of Modern Industry Fund, Bao Hongzhi, Director of Production and Executive Editor of Xinhua Client and other industry experts witnessed the launch ceremony. This study is another important milestone in Darwin's journey of innovative drug research.

Alitol is a class of cell-derived protein polymers that promote the repairing effects of damage in the nervous system. Previous studies have confirmed that Alitol's functions include reducing a variety of cellular stress responses, decreasing mitochondrial and lysosomal damage, and restoring normal metabolism in neurons, while inhibiting the over-activation of neuroinflammation. Through these mechanisms, it effectively relieves neuronal stress, enabling neurons to better mobilize their own repair capabilities and restore the function of the nervous system. This innovative mode of action of multi-targets and multi-pathways opens up new frontiers for the repair of nerve injury.

The ASSIST study focuses on the 72-hour window for medication use in the acute phase of stroke. In the clinical treatment of stroke, the 72-hour window means that more patients can receive effective treatment in time, which significantly reduces the rate of disability and mortality and brings new hope to patients. This study is not only a continuation and deepening of the previous research results, but also reflects the broad application prospect of Alitol in the treatment of neurological diseases. Through the continuous enrichment of mechanism research, the potential application of alitretol in clinical diseases will be further amplified, which is expected to bring benefits to more patients.

This study is the third indication study of Alitol in the field of neurological diseases after acromegaly and multiple system atrophy, and it is also the embodiment of the important results after the establishment of the joint laboratory between Tiantan Hospital and Darwin Bio. We believe that in the future, the Joint Laboratory will continue to play an important role in producing more scientific research results, and jointly promote innovation and progress in the field of neurological disease treatment, bringing more hope and possibilities to patients.